Clinical Trial Update: Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating erlotinib in patients with stage I-IIIA non-small cell lung cancer undergoing surgical resection has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib) (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED